Edition:
United States

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

4.95USD
21 Sep 2018
Change (% chg)

$-0.16 (-3.13%)
Prev Close
$5.11
Open
$5.13
Day's High
$5.13
Day's Low
$4.94
Volume
8,306
Avg. Vol
28,640
52-wk High
$6.30
52-wk Low
$1.91

Latest Key Developments (Source: Significant Developments)

Aptevo Therapeutics Q1 Loss Per Share $0.63
Thursday, 10 May 2018 09:00am EDT 

Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.63.QUARTERLY TOTAL REVENUES $4.1 MILLION VERSUS $2.1 MILLION.  Full Article

Aptevo Therapeutics Reports 2017 Financial Results And Provides Business Update
Tuesday, 13 Mar 2018 09:02am EDT 

March 13 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.APTEVO - ‍HAD CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 TOTALING $91.2 MILLION​.  Full Article

Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma
Tuesday, 28 Nov 2017 07:02am EST 

Nov 28 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA.APTEVO THERAPEUTICS INC- ‍EXPECTS TO FILE 2 IND APPLICATIONS IN 2018 FOR 2 BISPECIFIC ANTIBODY CANDIDATES, APVO436 AND APVO210​.  Full Article

Aptevo Therapeutics files mixed shelf of up to $150 mln
Monday, 13 Nov 2017 06:14am EST 

Nov 13 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​.  Full Article

Aptevo Therapeutics reports third quarter 2017 financial results
Thursday, 9 Nov 2017 04:30pm EST 

Nov 9 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics reports third quarter 2017 financial results.Q3 earnings per share $1.77.  Full Article

APTEVO THERAPEUTICS ‍AMENDS TERMS OF CREDIT AGREEMENT
Thursday, 28 Sep 2017 04:45pm EDT 

Sept 28 (Reuters) - Aptevo Therapeutics Inc ::APTEVO THERAPEUTICS INC - ‍AMENDED TERMS OF A CREDIT AGREEMENT INITIALLY EXECUTED WITH MIDCAP FINANCIAL TRUST IN AUGUST 2016​.APTEVO THERAPEUTICS INC - AS PART OF AMENDMENT, COMPANIES HAVE AGREED TO ELIMINATE OPTION FOR A SECOND TRANCHE OF $15 MILLION.APTEVO THERAPEUTICS INC- AMENDMENT ALLOWS CO TO RETAIN TRANCHE OF $20 MILLION, FUNDED IN AUG 2016.  Full Article

Aptevo Therapeutics signs agreement for up to $74.5 mln to sell Hyperimmune Commercial Products
Thursday, 31 Aug 2017 05:16pm EDT 

Aug 31 (Reuters) - Aptevo Therapeutics Inc ::Aptevo Therapeutics signs agreement for up to $74.5 million to sell hyperimmune commercial products.Aptevo - deal valued at up to $74.5 million, including an upfront payment of $65 million, and an additional potential milestone payment of up to $7.5 million​.Aptevo Therapeutics Inc - co may receive up to $2 million related to collection of certain accounts receivable after closing of deal.Aptevo Therapeutics Inc - ‍agreed to sell its three marketed hyperimmune products, winrho sdf, hepagam b, and varizig, to saol therapeutics​.Aptevo Therapeutics - ‍anticipates that proceeds from sale of hyperimmune products will be used to satisfy current debt obligation to midcap financial​.Aptevo Therapeutics - ‍anticipates that proceeds from sale of hyperimmune products will be used to advance clinical and preclinical adaptir candidates​.  Full Article

Aptevo Therapeutics Inc's reports Q2 loss per share $0.53
Thursday, 10 Aug 2017 09:02am EDT 

Aug 10 (Reuters) - Aptevo Therapeutics Inc ::Aptevo Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.53.Aptevo Therapeutics Inc - total product sales revenue was $10.8 million for three months ended June 30, 2017, compared to $10.2 million for same period in 2016.  Full Article

Aptevo Therapeutics and Alligator Bioscience to co-develop novel bispecific antibody
Friday, 21 Jul 2017 01:00am EDT 

July 21 (Reuters) - ALLIGATOR BIOSCIENCE AB :APTEVO THERAPEUTICS AND ALLIGATOR BIOSCIENCE ANNOUNCE PLANS TO CO-DEVELOP NOVEL BISPECIFIC ANTIBODY FOR TUMOR-DIRECTED IMMUNOTHERAPY.‍PARTIES WILL JOINTLY OWN AND SHARE EQUALLY IN DEVELOPMENT COSTS ASSOCIATED WITH ADVANCING THIS CANDIDATE THROUGH TO END OF PHASE 2 CLINICAL DEVELOPMENT​.  Full Article

Aptevo Therapeutics' unit, CMC ICOS Biologics enter non-exclusive amended and restated commercial supply agreement
Thursday, 22 Jun 2017 07:30am EDT 

June 22 (Reuters) - Aptevo Therapeutics Inc :Aptevo Therapeutics- on June 17, unit and CMC ICOS biologics entered non-exclusive amended and restated commercial supply agreement - SEC filing.Aptevo -pursuant to terms of restated supply agreement, CMC agreed to manufacture product in quantity of batches provided to CMC on a 24 month rolling forecast.Aptevo Therapeutics - restated supply deal supersedes, restates,replaces, as of restatement date, original supply agreement dated as of June 17, 2011.Aptevo Therapeutics Inc says beginning 2018, batch minimum will be four batches and batch maximum will be ten batches in a calendar year.Aptevo Therapeutics Inc says any batches ordered in a campaign should receive an incremental discounted price.Aptevo Therapeutics Inc - in accordance with agreement, $7.0 million reserve held by CMC shall be applied to any batches manufactured through end of 2017.Aptevo Therapeutics - in accordance with agreement, remaining amounts outstanding at year end shall be paid to Aptevo bio on or before Dec 31, 2017.Aptevo Therapeutics Inc - On June 19, unit of co and Morphosys AG entered fourth amendment to license and co-development agreement.Aptevo Therapeutics - pursuant to amendment, unit,Morphosys agreed Aptevo research and development continue to bear 75% of development costs with respect to MOR209/ES414.  Full Article